A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
about
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor modelNonsurgical treatment of recurrent glioblastomaMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesAdaptation to antiangiogenic therapy in neurological tumorsTissue concentration of systemically administered antineoplastic agents in human brain tumors.Experimental approaches for the treatment of malignant gliomas.Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.Glial progenitors as targets for transformation in glioma.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiformeNT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling.Drosophila melanogaster as a model system for human brain cancers.Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor responsePhase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20.Supramolecular Probes for Assessing Glutamine Uptake Enable Semi-Quantitative Metabolic Models in Single Cells.Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectivenessTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors.Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.A validated tumorgraft model reveals activity of dovitinib against renal cell carcinomaEnhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaMulti-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.Anti-cancer Therapies in High Grade Gliomas.Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.Standards of care and novel approaches in the management of glioblastoma multiforme.Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
P2860
Q21133610-9C466EA3-E150-4FBE-AB81-732D6C193C9FQ26795560-A1D50744-87BB-4758-BA2A-095FEA422A4EQ26822717-B826407E-74B7-4780-87C6-3A6E82ABD8CFQ26829873-0D95B141-4AFC-4841-B764-1FF80B69E0B1Q26862516-F911F1FA-DEDC-4655-B0B8-FB5985535EBEQ28082908-DB8C006E-83D1-4E64-96C9-8098C13BEE6AQ33844823-27F333C2-7F28-4C07-B0B6-C08EE77179BFQ34127138-6A2AD4BD-8722-47A3-B169-CFBE196FCCB7Q34480689-9F4EA4B8-CD96-4783-AF9C-06D15D174E0AQ34722457-4FB97266-403A-475C-A36F-7DD641713194Q34735661-44DFDA58-688D-44F3-83AE-CA2D1867E9DCQ34778047-718DE44F-F71A-4235-9942-C9AE5AB4347AQ34848038-9F71EB15-D1DE-45EB-AA8A-D2897DDC840AQ35027024-6ED28BE1-2AA9-4AB8-BA00-34F86C5612F8Q35190966-CCADB0CD-E516-482B-97F6-31E25C28CCCCQ35201465-38F9C62B-80E5-4165-8F68-9E946A803033Q35202307-073D8CD8-AD39-400E-8E02-15A2502AAE4DQ35566228-8F4904D0-0F0F-44F7-B130-A9E054146F1EQ35779256-A5369552-6B3D-4ECF-9BC4-258AAD6A8732Q35788884-F4FDB38F-C778-44F7-912A-AD9F3D7EB147Q35830062-C58068D9-6155-4DAC-8E3A-374BBB883E84Q35936244-784C7523-CF51-483C-BB61-B882BE00B626Q36062158-AE28CBFE-8AE6-40D8-AAA3-2D6B54D4F34CQ36234132-73938500-1D64-4FD2-BC54-A838EAB03B45Q36297064-ACC6A536-3A72-4F04-8B49-DC0F95796706Q36329368-86DFBE49-C593-4AF3-B603-6B27531C2FCAQ36497633-D63297E2-E9A9-4416-96C4-33F2E6142D27Q36606040-F6EB3FC0-7D1F-4A38-BAF4-EEA47FAE5314Q36613936-448FCE50-2918-45C3-BD56-3E358A0BAE67Q36682422-AD9FFAB3-2A3B-4BEF-9823-59A4F93E9452Q36713494-5199DE3F-8E08-458B-822A-118D9B265A20Q36782767-01F4BB93-D4ED-4F6D-928B-A3DB72A805F5Q36913828-B883EC9B-9A01-48C9-995F-4F34C690D236Q36949546-9D1A77BC-F3FF-4016-862D-80CE38784FF3Q37225334-C23A3721-2606-48B5-B101-5C7824F16979Q37290626-09B4509A-2B73-4CFE-9001-21A7D45FF4F7Q37308322-594A0E8F-6A0E-408D-A538-5ADCAF0C162BQ37471694-D3FE22D0-8605-4630-94F0-91B3EAAD6BE6Q37525881-C4AE4319-ED99-4CC1-909B-19EAD11B5D8AQ37641248-18E3D817-F20D-4AF4-BEE8-34A7CB5408DE
P2860
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@ast
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@en
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@nl
type
label
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@ast
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@en
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@nl
prefLabel
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@ast
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@en
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@nl
P2093
P2860
P356
P1433
P1476
A phase II trial of erlotinib ...... tiforme postradiation therapy.
@en
P2093
Andrew B Lassman
Frank Lieberman
H Ian Robins
Howard A Fine
Janet Dancey
Jeffrey J Raizer
John G Kuhn
Kathleen R Lamborn
Kenneth A Aldape
Lauren E Abrey
P2860
P304
P356
10.1093/NEUONC/NOP015
P577
2009-12-14T00:00:00Z